GSK plc reported positive results from its DREAMM-8 trial of Blenrep for treating relapsed/refractory multiple myeloma, which showed significant improvement in progression-free survival over standard treatment; the trial was unblinded early based on an independent committee's recommendation on March 7, 2024.